US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

693.03

+4.110.60%

Number of Gainers:71

Number of Losers:69

Number of Flat:14

PE:- -

High:698.21

Open:689.82

Low:685.07

Close:688.92

Volume:272.16M

Turnover:8.90B

Market Cap:479.85B

Float Cap:365.12B

Loading ...

Allogene Therapeutics Announces Participation in September Investor Conference

Press Release: Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

TransCode Says Preclinical Study Shows Survival Benefit for TTX-MC138 in Breast Cancer Bone Metastasis Model

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

MT Newswires Live

Mobix Labs, - Announces Definitive Agreement to Buy Vision Aerial

THOMSON REUTERS

Mobix Labs - Vision Aerial Acquisition Expected to Close in Q4 2026, Subject to Conditions

THOMSON REUTERS

Mobix Labs, - Vision Aerial Projects 46% Revenue Growth in 2026 and 93% in 2027

THOMSON REUTERS

Press Release: Mobix Labs' Pending Drone Acquisition, Vision Aerial, Projects 93% Revenue Growth

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

Kazia Therapeutics Unveils New Investor-Focused Website

Clear Secure Partners with CrowdStrike to Integrate Clear1 Identity Verification into Falcon Platform

Stevanato Group (STVN) Receives a Hold from Morgan Stanley

Zhihu Details July–August 2026 Share Buybacks and Governance Updates in Form 6-K

Kazia Therapeutics Secures $40 Million U.S. Offering to Accelerate Paxalisib Oncology Program

Macquarie Upgrades Chagee to Outperform From Neutral, $10.20 Price Target

MT Newswires Live

Alzamend Neuro Director Milton C. Ault III Sells 2,000 Shares Worth $3,116.20

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Waterdrop Founder Shen Peng Appointed Vice Chairman of HKU Business School North China Alumni Association

Cutia Therapeutics Accelerates Commercial Push in China’s Dermatology Market

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BK4539/news?page=44"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":693.02655,"timestamp":1789156799999,"preClose":688.91504,"halted":0,"volume":272157313,"delay":0,"changeRate":0.005968,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":4.111511,"latestTime":"09-11 16:00:00 EDT","open":689.8237,"high":698.2087,"low":685.0665,"amount":8901943117.280722,"amplitude":0.019077,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.322141,"peRate":139.801509,"turnoverRate":0.021443,"increases":71,"decrements":69,"flats":10,"marketCap":479852364396.5,"floatMarketCap":365120021896},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":698.2087,"amplitude":0.019077,"preClose":688.91504,"low":685.0665,"pbRate":"5.322141","latestPrice":693.02655,"volume":272157313,"delay":0,"open":689.8237,"prevYearClose":881.5255,"prevWeekClose":725.2816,"prevMonthClose":701.0681,"prevQuarterClose":742.922,"fiveDayClose":733.4782,"twentyDayClose":682.8836,"sixtyDayClose":729.1859,"secType":"PLATE","market":"US","turnoverRate":0.021443,"peRate":139.801509,"marketCap":479852364396.5,"floatMarketCap":365120021896,"timestamp":1789156799999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":71,"down":69,"flat":14},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:44,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663092840","title":"Allogene Therapeutics Announces Participation in September Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2663092840","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663092840?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:30","pubTimestamp":1788179400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353301/0/en/allogene-therapeutics-announces-participation-in-september-investor-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003607","title":"Press Release: Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003607","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003607?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:30","pubTimestamp":1788179400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (\"Acrivon\" or \"Acrivon Therapeutics\") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008171","title":"TransCode Says Preclinical Study Shows Survival Benefit for TTX-MC138 in Breast Cancer Bone Metastasis Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008171","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008171?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:07","pubTimestamp":1788178055,"startTime":"0","endTime":"0","summary":"TransCode says preclinical study shows survival benefit for TTX-MC138 in breast cancer bone metastasis modelTransCode Therapeutics disclosed peer-reviewed preclinical data showing its lead candidate T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL7NnQJj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008151","title":"Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008151","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008151?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:04","pubTimestamp":1788177853,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics (HKG:1477) enrolled the first patient in a phase III clinical trial of OT-202.The trial is studying the drug for the treatment of dry eye disease in China, according to a Monday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK1574","BK1191","BK4007","01477","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663700860","title":"Mobix Labs, - Announces Definitive Agreement to Buy Vision Aerial","url":"https://stock-news.laohu8.com/highlight/detail?id=2663700860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663700860?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:02","pubTimestamp":1788177773,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S06T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MOBX","BK4141","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663200896","title":"Mobix Labs - Vision Aerial Acquisition Expected to Close in Q4 2026, Subject to Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2663200896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663200896?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:02","pubTimestamp":1788177773,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S06T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4141","MOBX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006115","title":"Mobix Labs, - Vision Aerial Projects 46% Revenue Growth in 2026 and 93% in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006115?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:02","pubTimestamp":1788177773,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S06T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","MOBX","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663085520","title":"Press Release: Mobix Labs' Pending Drone Acquisition, Vision Aerial, Projects 93% Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2663085520","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663085520?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"-- 46% projected revenue growth in 2026; 93% in 2027 ---- U.S. Navy and L3Harris among Vision Aerial customers --IRVINE, Calif. & BOZEMAN, Mont.--(BUSINESS WIRE)--August 31, 2026--Mobix Labs, Inc. (Na","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MOBX","BK4141","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008480","title":"Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008480","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008480?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353254/0/en/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-meeting-for-phase-3-registration-study-of-cad-1005-in-heparin-induced-thrombocytopenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","BK4528","IE0031619046.USD","BK4173","HIT","BK4585","LENZ","BK4023","BK4613","BK4139","KD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","LABU","BK4007","BK4588","IE00B7SZL793.SGD","BK4539","SAP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008468","title":"Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008468","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008468?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Aug.  31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353265/0/en/chemomab-therapeutics-to-present-at-h-c-wainwright-28th-annual-global-investor-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663600856","title":"Kazia Therapeutics Unveils New Investor-Focused Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600856","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600856?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:57","pubTimestamp":1788177432,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics ( ($KZIA) ) has shared an announcement. On August 28, 2026, Kazia Therapeutics launched a new corporate website at www.kaziatx.c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-unveils-new-investor-focused-website?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-unveils-new-investor-focused-website?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663842008","title":"Clear Secure Partners with CrowdStrike to Integrate Clear1 Identity Verification into Falcon Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2663842008","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663842008?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:55","pubTimestamp":1788177344,"startTime":"0","endTime":"0","summary":"Clear Secure partners with CrowdStrike to integrate CLEAR1 identity verification into Falcon platformCLEAR entered a strategic partnership with CrowdStrike to integrate CLEAR1 verified identity into t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL27ZKbZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRWD","LU1917777945.USD","IE00B19Z9P08.USD","LU2272731782.SGD","LU1548497426.USD","LU0081259029.USD","LU1992135472.HKD","LU2125909916.SGD","LU2264538146.SGD","IE00B894F039.SGD","BK4598","CRWC","BK4585","LU2125909247.SGD","BK4539","LU1951200564.SGD","LU2211815571.USD","LU1951198990.SGD","LU2023250504.SGD","CRWL","HAKY","BK4588","YOU","IE00B19Z9Z06.USD","LU0266013472.USD","LU0719512351.SGD","LU1804176565.USD","WCBR","AIPI","BK4097","IE00BZ9MQY76.HKD","PSWD","LU2272731600.USD","LU1992135399.USD","BK4532","SPAM","LU2106854487.HKD","LU2265009873.SGD","LU1923622614.USD","BUG","LU1720051108.HKD","LU1923623000.USD","BK4551","IGV","LU1720051017.SGD","BK4560","CIBR","LU1064131342.USD","LU1988902786.USD","CLOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663500859","title":"Stevanato Group (STVN) Receives a Hold from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2663500859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663500859?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:55","pubTimestamp":1788177339,"startTime":"0","endTime":"0","summary":"In a report released today, Kallum Titchmarsh from Morgan Stanley maintained a Hold rating on Stevanato Group, with a price target of $20.00. Titch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stevanato-group-stvn-receives-a-hold-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stevanato-group-stvn-receives-a-hold-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["STVN","BK4121","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077728","title":"Zhihu Details July–August 2026 Share Buybacks and Governance Updates in Form 6-K","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077728","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077728?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:19","pubTimestamp":1788175189,"startTime":"0","endTime":"0","summary":"The latest update is out from Zhihu ( ($ZH) ). Zhihu filed a Form 6-K for August 2026 detailing several Hong Kong Next Day Disclosure Returns cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zhihu-details-july-august-2026-share-buybacks-and-governance-updates-in-form-6-k?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zhihu-details-july-august-2026-share-buybacks-and-governance-updates-in-form-6-k?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","BK4539","BK4077","BK4509","ZH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077779","title":"Kazia Therapeutics Secures $40 Million U.S. Offering to Accelerate Paxalisib Oncology Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077779","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077779?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:19","pubTimestamp":1788175180,"startTime":"0","endTime":"0","summary":"An announcement from Kazia Therapeutics ( ($KZIA) ) is now available. On August 28, 2026, Kazia Therapeutics entered an underwriting agreement for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-secures-40-million-u-s-offering-to-accelerate-paxalisib-oncology-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-secures-40-million-u-s-offering-to-accelerate-paxalisib-oncology-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ","AAQC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663958077","title":"Macquarie Upgrades Chagee to Outperform From Neutral, $10.20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2663958077","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663958077?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:09","pubTimestamp":1788174561,"startTime":"0","endTime":"0","summary":"Chagee (CHA) has an average rating of overweight and mean price target of $15.21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348766576.USD","BK4539","BK4526","CHA","LU0348767384.USD","BK4610","BK4209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077385","title":"Alzamend Neuro Director Milton C. Ault III Sells 2,000 Shares Worth $3,116.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077385","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077385?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:03","pubTimestamp":1788174204,"startTime":"0","endTime":"0","summary":"Alzamend Neuro director Milton C. Ault III sells 2,000 shares worth $3,116.20Director Milton C. Ault III sold 2,000 Alzamend Neuro common shares on Aug. 26, 2026.Sale priced at USD 1.56 per share; dir","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5VZc2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alzamend Neuro Director Milton C. Ault III Sells 2,000 Shares Worth $3,116.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALZN","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663318077","title":"Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2663318077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663318077?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:00","pubTimestamp":1788174000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353154/0/en/beam-therapeutics-to-participate-in-upcoming-september-2026-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192275043","title":"Waterdrop Founder Shen Peng Appointed Vice Chairman of HKU Business School North China Alumni Association","url":"https://stock-news.laohu8.com/highlight/detail?id=1192275043","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192275043?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:12","pubTimestamp":1788171153,"startTime":"0","endTime":"0","summary":"On August 30, Waterdrop Inc. (NYSE: WDH) founder and CEO Shen Peng was appointed as Vice Chairman of the Hong Kong University (HKU) Business School's North China Alumni Association, with a term...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4509","BK4539","BK4173","WDH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071481","title":"Cutia Therapeutics Accelerates Commercial Push in China’s Dermatology Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663071481?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:50","pubTimestamp":1788169824,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics ( ($HK:2487) ) just unveiled an announcement. Cutia Therapeutics reported solid progress in its interim business update for the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cutia-therapeutics-accelerates-commercial-push-in-chinas-dermatology-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cutia-therapeutics-accelerates-commercial-push-in-chinas-dermatology-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":45,"pageCount":44,"totalSize":898,"code":"91000000","status":"200"}]}}